| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Therapeutic Solutions International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00055 |
| 52 Week High | US$0.0033 |
| 52 Week Low | US$0.0005 |
| Beta | 1.33 |
| 1 Month Change | -38.89% |
| 3 Month Change | -57.69% |
| 1 Year Change | -83.08% |
| 3 Year Change | -99.15% |
| 5 Year Change | -82.81% |
| Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| TSOI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -21.4% | -0.6% | 1.0% |
| 1Y | -83.1% | 10.6% | 21.9% |
Return vs Industry: TSOI underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: TSOI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TSOI volatility | |
|---|---|
| TSOI Average Weekly Movement | 22.2% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TSOI's share price has been volatile over the past 3 months.
Volatility Over Time: TSOI's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3 | Tim Dixon | www.therapeuticsolutionsint.com |
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production.
Therapeutic Solutions International, Inc. Fundamentals Summary
| TSOI fundamental statistics | |
|---|---|
| Market cap | US$2.33m |
| Earnings (TTM) | -US$2.17m |
| Revenue (TTM) | US$98.99k |
23.5x
P/S Ratio-1.1x
P/E RatioIs TSOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSOI income statement (TTM) | |
|---|---|
| Revenue | US$98.99k |
| Cost of Revenue | US$36.77k |
| Gross Profit | US$62.23k |
| Other Expenses | US$2.23m |
| Earnings | -US$2.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00051 |
| Gross Margin | 62.86% |
| Net Profit Margin | -2,191.86% |
| Debt/Equity Ratio | 59.5% |
How did TSOI perform over the long term?
See historical performance and comparison